Q-omics provides the consensus-scored ANGPTL2 profile across patient tissues and cancer cell-line models. ANGPTL2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ANGPTL2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ANGPTL2 protein abundance shows 28,254 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LGG, KIRC, and PDAC as cancer lineages where ANGPTL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANGPTL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANGPTL2 survival associations across molecular data types. ANGPTL2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANGPTL2 RNA expression–survival associations across cancer types. High ANGPTL2 expression shows unfavorable associations in KICH, KIRP and UVM, but favorable associations in LGG, DLBC and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ANGPTL2 RNA expression.
This table summarizes ANGPTL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANGPTL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANGPTL2 shows lower tumor expression in BLCA, KICH and BRCA and higher tumor expression in KIRC, LUAD and HNSC. The KIRC box plot shows higher ANGPTL2 RNA expression in tumor versus normal tissue (log2 FC = +1.646, t-test p < 0.001).
This table shows molecular features associated with ANGPTL2 in patient tissues and cancer cell lines. In patient samples, ANGPTL2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANGPTL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
